BusinessBioMarin Announces EMA Validation of Brineura™ (Cerliponase Alfa) Marketing Authorization Application for Treatment of CLN2 Disease, a Form of Batten DiseaseBy Nasdaq OMXSep 15, 2016, 12:38 PM UTC